Tilray (NASDAQ: TLRY) is one of 33 public companies in the “Medicinals & botanicals” industry, but how does it weigh in compared to its rivals? We will compare Tilray to similar companies based on the strength of its dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.
Institutional and Insider Ownership
10.4% of Tilray shares are held by institutional investors. Comparatively, 21.6% of shares of all “Medicinals & botanicals” companies are held by institutional investors. 16.8% of Tilray shares are held by insiders. Comparatively, 25.8% of shares of all “Medicinals & botanicals” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This table compares Tilray and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
Tilray has a beta of 2.92, indicating that its share price is 192% more volatile than the S&P 500. Comparatively, Tilray’s rivals have a beta of 2.56, indicating that their average share price is 156% more volatile than the S&P 500.
This is a summary of recent recommendations and price targets for Tilray and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Tilray presently has a consensus target price of $12.73, indicating a potential upside of 128.91%. As a group, “Medicinals & botanicals” companies have a potential upside of 106.17%. Given Tilray’s higher probable upside, analysts clearly believe Tilray is more favorable than its rivals.
Earnings and Valuation
This table compares Tilray and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Tilray||$166.98 million||-$321.17 million||-3.29|
|Tilray Competitors||$218.50 million||-$99.79 million||1.73|
Tilray’s rivals have higher revenue and earnings than Tilray. Tilray is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Tilray rivals beat Tilray on 9 of the 13 factors compared.
Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Nanaimo, Canada.
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.